Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 3000+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Jul 9, 2026

•

3 min read

Biotech & Pharma Updates | July 9, 2026

🧬 Ipsen's Dysport (abobotulinumtoxinA) meets Ph3 goals in both episodic and chronic migraine trials, Sanofi offers EU concessions to halt probe over misleading flu vaccine campaign against CSL Seqirus, MindRank raises $52M Series B, advancing AI-discovered oral GLP-1 obesity pill to Phase III

Christian Cuchapin, +1

Jul 8, 2026

•

3 min read

Biotech & Pharma Updates | July 8, 2026

🧬 Vera Therapeutics' Trutakna (atacicept) receives FDA accelerated approval for IgA nephropathy targeting APRIL and BAFF, AstraZeneca, Sino Biopharmaceutical strike ex-China licensing deal for COPD candidate TQC3721, $200M upfront, up to $1.9B total, Evonik invests $100M in Indiana API plant to meet surging U.S. CDMO demand

Christian Cuchapin, +1

Jul 7, 2026

•

3 min read

Biotech & Pharma Updates | July 7, 2026

🧬 Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals for $10B in largest-ever deal, expanding into endocrine diseases, Kalohexis files confidential IPO, developing melanocortin-based obesity and cancer cachexia treatments, Compass Pathways' COMP360 (psilocybin) demonstrates durable Ph3 response in treatment-resistant depression

Christian Cuchapin, +1

Jul 6, 2026

•

3 min read

Biotech & Pharma Updates | July 6, 2026

🧬 Novartis to acquire Myricx Bio for up to $1.5B, expanding ADC cancer pipeline with novel NMT inhibitor payloads, Scribe Therapeutics files for IPO, advancing lipid-lowering genetic medicines through clinical trials, Celea Therapeutics raises $180M venture round to advance IPF drug deupirfenidone into late-stage trials

Christian Cuchapin, +1

Jul 2, 2026

•

3 min read

Biotech & Pharma Updates | July 2, 2026

🧬 Roche's (divarasib) beats Amgen's Lumakras and BMS's Krazati in Ph3 KRAS G12C-mutated non-small cell lung cancer trial, BridgeBio attracts $1B in convertible preferred equity from Sixth Street, HealthCare Royalty for drug launches, AstraZeneca, CSPC Pharmaceutical Group partner on siRNA kidney disease therapies, $30M upfront, $1.77B total

Christian Cuchapin, +1

Jul 1, 2026

•

3 min read

Biotech & Pharma Updates | July 1, 2026

🧬 FDA approves Orca Bio's Tregzi for graft-versus-host disease prevention in blood cancer patients following Ph3 success, Ipsen to acquire Memo Therapeutics for up to $796M, targeting rare BK virus kidney transplant complication, Anthropic launches Claude Science AI workbench and internal drug discovery program targeting neglected diseases

Christian Cuchapin, +1

Biotech & Pharma Updates | June 30, 2026

Jun 30, 2026

•

3 min read

Biotech & Pharma Updates | June 30, 2026

🧬 FDA selects Eli Lilly, Regeneron, Fujifilm, Kriya Therapeutics, others for PreCheck Pilot Program to boost U.S. drug manufacturing, BeOne's Brukinsa (zanubrutinib) meets Ph3 goal, reducing progression risk by 43% in first-line mantle cell lymphoma, Boulevard Bio, Metis TechBio strike $1.6B deal for trispecific TCE MTS-128 targeting autoimmune diseases

Christian Cuchapin, +1

Biotech & Pharma Updates | June 29, 2026

Jun 29, 2026

•

3 min read

Biotech & Pharma Updates | June 29, 2026

🧬 Ipsen to acquire Kartos Therapeutics for up to $1.75B, adding myelofibrosis candidate navtemadlin to oncology pipeline, Viridian Therapeutics' Lumvoa (veligrotug-vvze) wins FDA approval for thyroid eye disease across active and chronic disease, Zymeworks to acquire Theravance for $929M, gaining approved COPD drug Yupelri and lucrative royalty deals

Christian Cuchapin, +1

Biotech & Pharma Updates | June 26, 2026

Jun 26, 2026

•

3 min read

Biotech & Pharma Updates | June 26, 2026

🧬 FDA accepts Replimune's RP1 resubmission for advanced melanoma, sets early August decision after two prior rejections, Bayer wins Supreme Court ruling overturning $1.25M Roundup cancer verdict, shares surge 19%, Amgen's Tavneos loses EU endorsement over data integrity concerns ahead of FDA hearing

Christian Cuchapin, +1

1...43 44 45 46 47...54

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | July 9, 2026

Biotech & Pharma Updates | July 8, 2026

Biotech & Pharma Updates | July 7, 2026

Biotech & Pharma Updates | July 6, 2026

Biotech & Pharma Updates | July 2, 2026

Biotech & Pharma Updates | July 1, 2026

Biotech & Pharma Updates | June 30, 2026

Biotech & Pharma Updates | June 29, 2026

Biotech & Pharma Updates | June 26, 2026

TLDR Biotech

FAQ

Media Partners